474 related articles for article (PubMed ID: 28060563)
1. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
3. The role of SLAMF7 in multiple myeloma: impact on therapy.
Boudreault JS; Touzeau C; Moreau P
Expert Rev Clin Immunol; 2017 Jan; 13(1):67-75. PubMed ID: 27376202
[TBL] [Abstract][Full Text] [Related]
4. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
[TBL] [Abstract][Full Text] [Related]
5. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
Mateos MV; Granell M; Oriol A; Martinez-Lopez J; Blade J; Hernandez MT; Martín J; Gironella M; Lynch M; Bleickardt E; Paliwal P; Singhal A; San-Miguel J
Br J Haematol; 2016 Nov; 175(3):448-456. PubMed ID: 27434748
[TBL] [Abstract][Full Text] [Related]
6. An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.
Passey C; Mora J; Dodge R; Gibiansky L; Sheng J; Roy A; Bello A; Gupta M
AAPS J; 2017 Mar; 19(2):557-567. PubMed ID: 28070715
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
8. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment.
Magen H; Muchtar E
Ther Adv Hematol; 2016 Aug; 7(4):187-95. PubMed ID: 27493709
[TBL] [Abstract][Full Text] [Related]
9. Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
Iida S; Nagai H; Kinoshita G; Miyoshi M; Robbins M; Pandya D; Bleickardt E; Chou T
Int J Hematol; 2017 Mar; 105(3):326-334. PubMed ID: 27848182
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
12. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Lonial S; Dimopoulos M; Palumbo A; White D; Grosicki S; Spicka I; Walter-Croneck A; Moreau P; Mateos MV; Magen H; Belch A; Reece D; Beksac M; Spencer A; Oakervee H; Orlowski RZ; Taniwaki M; Röllig C; Einsele H; Wu KL; Singhal A; San-Miguel J; Matsumoto M; Katz J; Bleickardt E; Poulart V; Anderson KC; Richardson P;
N Engl J Med; 2015 Aug; 373(7):621-31. PubMed ID: 26035255
[TBL] [Abstract][Full Text] [Related]
13. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
Dimopoulos MA; Lonial S; Betts KA; Chen C; Zichlin ML; Brun A; Signorovitch JE; Makenbaeva D; Mekan S; Sy O; Weisel K; Richardson PG
Cancer; 2018 Oct; 124(20):4032-4043. PubMed ID: 30204239
[TBL] [Abstract][Full Text] [Related]
14. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Boudreault JS; Touzeau C; Moreau P
Expert Rev Hematol; 2017 Mar; 10(3):207-215. PubMed ID: 28110581
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.
Ide T; Osawa M; Sanghavi K; Vezina HE
Cancer Chemother Pharmacol; 2022 Jan; 89(1):129-140. PubMed ID: 34825942
[TBL] [Abstract][Full Text] [Related]
16. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
Berenson J; Manges R; Badarinath S; Cartmell A; McIntyre K; Lyons R; Harb W; Mohamed H; Nourbakhsh A; Rifkin R
Am J Hematol; 2017 May; 92(5):460-466. PubMed ID: 28213943
[TBL] [Abstract][Full Text] [Related]
18. Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.
Eleutherakis-Papaiakovou E; Gavriatopoulou M; Ntanasis-Stathopoulos I; Kastritis E; Terpos E; Dimopoulos MA
Expert Rev Anticancer Ther; 2019 Nov; 19(11):921-928. PubMed ID: 31679403
[No Abstract] [Full Text] [Related]
19. FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
Gormley NJ; Ko CW; Deisseroth A; Nie L; Kaminskas E; Kormanik N; Goldberg KB; Farrell AT; Pazdur R
Clin Cancer Res; 2017 Nov; 23(22):6759-6763. PubMed ID: 28249893
[TBL] [Abstract][Full Text] [Related]
20. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
Usmani SZ; Sexton R; Ailawadhi S; Shah JJ; Valent J; Rosenzweig M; Lipe B; Zonder JA; Fredette S; Durie B; Hoering A; Bartlett B; Orlowski RZ
Blood Cancer J; 2015 Aug; 5(8):e334. PubMed ID: 26252787
[No Abstract] [Full Text] [Related]
[Next] [New Search]
